Drugs / ETV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04147208 | Feb 2019 → Jun 2022 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04147208 ↗ |
| Route | Oral | “Administered orally ETV 0.5 mg once daily in fasted state” NCT04147208 ↗ |